Laura Leyva

3.2k total citations
71 papers, 1.7k citations indexed

About

Laura Leyva is a scholar working on Pathology and Forensic Medicine, Immunology and Oncology. According to data from OpenAlex, Laura Leyva has authored 71 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pathology and Forensic Medicine, 27 papers in Immunology and 18 papers in Oncology. Recurrent topics in Laura Leyva's work include Multiple Sclerosis Research Studies (30 papers), T-cell and B-cell Immunology (13 papers) and Drug-Induced Adverse Reactions (11 papers). Laura Leyva is often cited by papers focused on Multiple Sclerosis Research Studies (30 papers), T-cell and B-cell Immunology (13 papers) and Drug-Induced Adverse Reactions (11 papers). Laura Leyva collaborates with scholars based in Spain, United Kingdom and United States. Laura Leyva's co-authors include Cristobalina Mayorga, Óscar Fernández, Marı́a José Torres, S. Posadas, M. Blanca, Miguel Blanca, Begoña Oliver‐Martos, Carlos Juárez, Fuencisla Matesanz and Marı́a Fedetz and has published in prestigious journals such as PLoS ONE, Stroke and Scientific Reports.

In The Last Decade

Laura Leyva

68 papers receiving 1.7k citations

Peers

Countries citing papers authored by Laura Leyva

Since Specialization

Citations

This map shows the geographic impact of Laura Leyva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Leyva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Leyva more than expected).

Fields of papers citing papers by Laura Leyva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Leyva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Leyva. The network helps show where Laura Leyva may publish in the future.

Co-authorship network of co-authors of Laura Leyva

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Leyva. A scholar is included among the top collaborators of Laura Leyva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Leyva. Laura Leyva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations 2023 ·Frontiers in Immunology ·Nicolás Lundahl Ciano-Petersen, (unknown), (unknown), (unknown), J.L. Rodriguez-Bada, (unknown), (unknown), Laura Leyva, Pedro J. Serrano‐Castro, Ana Alonso, Begoña Oliver‐Martos	2
2	Activation of Macrophages by Lysophosphatidic Acid through the Lysophosphatidic Acid Receptor 1 as a Novel Mechanism in Multiple Sclerosis Pathogenesis 2020 ·Molecular Neurobiology ·(unknown), (unknown), (unknown), Óscar Fernández, Laura Leyva, Fernando Rodrı́guez de Fonseca, Jerold Chun, Céline Louapre, Anne Baron‐Van Evercooren, Violetta Zujovic, Guillermo Estivill‐Torrús, Beatriz García-Díaz	22
3	Skin Phototype Could Be a Risk Factor for Multiple Sclerosis 2020 ·Journal of Clinical Medicine ·(unknown), (unknown), (unknown), Begoña Oliver‐Martos, Celia Oreja‐Guevara, (unknown), Ana Alonso, Francisco Javier Barón-López, Laura Leyva, Óscar Fernández, María Jesús Pinto-Medel	0
4	Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNß in Multiple Sclerosis Patients According to the Therapeutic Response to IFNß 2017 ·PLoS ONE ·(unknown), María Jesús Pinto-Medel, (unknown), (unknown), Antônio Ponce de León, Miguel Guerrero, Óscar Fernández, Laura Leyva, Begoña Oliver‐Martos	14
5	The HLA DRB103:01 allele is associated with NMO regardless of the NMO-IgG status in Brazilian patients from Rio de Janeiro 2017 ·Journal of Neuroimmunology* ·(unknown), Óscar Fernández, Laura Leyva, (unknown), (unknown), (unknown), Regina Maria Papais Alvarenga	23
6	Cell-based product classification procedure: What can be done differently to improve decisions on borderline products? 2016 ·Cytotherapy ·Ander Izeta, Concha Herrera, Rosario Mata, Giuseppe Astori, Rosaria Giordano, Carmen Hernández, Laura Leyva, Salvador Arias, Salvador Oyonarte, Gloria Carmona, Natividad Cuende	15
7	Human Endogenous Retrovirus HERV-Fc1 Association with Multiple Sclerosis Susceptibility: A Meta-Analysis 2014 ·PLoS ONE ·(unknown), Jezabel Varadé, Marta García‐Montojo, Antonio Alcina, Marı́a Fedetz, Iraide Alloza, Ianire Astobiza, Laura Leyva, Óscar Fernández, Guillermo Izquierdo, Alfredo Rodríguez Antigüedad, Rafael Arroyo, Roberto Álvarez‐Lafuente, Koen Vandenbroeck, Fuencisla Matesanz, Elena Urcelay	28
8	Early development of anti-natalizumab antibodies in MS patients 2013 ·Journal of Neurology ·Begoña Oliver‐Martos, (unknown), (unknown), (unknown), Laura Leyva, Óscar Fernández	10
9	Predictors of Fatigue Severity in Early Systemic Sclerosis: A Prospective Longitudinal Study of the GENISOS Cohort 2011 ·PLoS ONE ·Shervin Assassi, Laura Leyva, Maureen D. Mayes, Roozbeh Sharif, (unknown), Michael A. Fischbach, Ngan Nguyen, John D. Reveille, Emilio B. González, Terry A. McNearney, (unknown)	27
10	Tag-SNP analysis of the GFI1-EVI5-RPL5-FAM69 risk locus for multiple sclerosis 2010 ·European Journal of Human Genetics ·Antonio Alcina, Óscar Fernández, Juan R. González, (unknown), Marı́a Fedetz, Dorothy Ndagire, Laura Leyva, (unknown), (unknown), Concepción Delgado, Miguel Lucas, Guillermo Izquierdo, Fuencisla Matesanz	20
11	Neutralizing antibodies against IFN beta in patients with multiple sclerosis: A comparative study of two cytopathic effect tests (CPE) for their detection 2009 ·Journal of Immunological Methods ·Begoña Oliver‐Martos, (unknown), Cristobalina Mayorga, María Jesús Pinto-Medel, Laura Leyva, Carlos Lopez‐Gómez, Clotilde Marı́n, Gloria Luque Agulló, (unknown), Óscar Fernández	8
12	Multiple sclerosis in Gypsies from southern Spain: prevalence, mitochondrial DNA haplogroups and HLA class II association 2008 ·Tissue Antigens ·Óscar Fernández, Victoria Fernández, (unknown), Cristobalina Mayorga, Ana Alonso, Antônio Ponce de León, (unknown), (unknown), Gloria Luque Agulló, Enrique de Ramón, Abelardo Caballero, Laura Leyva	15
13	The T244I variant of the interleukin‐7 receptor‐alpha gene and multiple sclerosis 2008 ·Tissue Antigens ·Antonio Alcina, Marı́a Fedetz, Dorothy Ndagire, Óscar Fernández, Laura Leyva, María del Mar López-Guerrero, (unknown), Concepción Delgado, Fuencisla Matesanz	28
14	The high producer variant of the Fc-receptor like-3 (FCRL3) gene is involved in protection against multiple sclerosis 2008 ·Journal of Neuroimmunology ·Fuencisla Matesanz, Óscar Fernández, Roger L. Milne, Marı́a Fedetz, Laura Leyva, Miguel Guerrero, Concepción Delgado, Miguel Lucas, Guillermo Izquierdo, Antonio Alcina	36
15	Interferon receptor expression in multiple sclerosis patients 2007 ·Journal of Neuroimmunology ·Begoña Oliver‐Martos, Cristobalina Mayorga, Victoria Fernández, Laura Leyva, Antônio Ponce de León, Gloria Luque Agulló, (unknown), (unknown), María Jesús Pinto-Medel, Enrique de Ramón, Eva María Blanco, Ana Alonso, Óscar Fernández	19
16	IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response 2005 ·Journal of Neuroimmunology ·Laura Leyva, Óscar Fernández, Marı́a Fedetz, (unknown), Victoria Fernández, Begoña Oliver‐Martos, Antônio Ponce de León, María Jesús Pinto-Medel, Cristobalina Mayorga, Miguel Guerrero, Gloria Luque Agulló, Antonio Alcina, Fuencisla Matesanz	69
17	Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity 2002 ·Journal of Allergy and Clinical Immunology ·S. Posadas, (unknown), Marı́a José Torres, Cristobalina Mayorga, Laura Leyva, Elena G. Sánchez, Javier Álvarez, Antonino Romano, Carlos Juárez, Miguel Blanca	190
18	Delayed hypersensitivity to cefazolin: report on a case involving lymphocyte transformation studies with different cephalosporins 2001 ·Annals of Allergy Asthma & Immunology ·Antonino Romano, Marı́a José Torres, M. Di Fonso, Laura Leyva, Maria Andriolo, Rosa Pettinato, Miguel Blanca	11
19	Expression of the skin‐homing receptor in peripheral blood lymphocytes from subjects with nonimmediate cutaneousallergic drug reactions 2000 ·Allergy ·M. Blanca, Marı́a José Torres, Laura Leyva, Cristobalina Mayorga, S. Posadas, Louis Gonzalez, Javier Fernández, (unknown), Luis F. Santamaria‐Babí	63
20	Preferential Expression of the Skin–Homing Receptor CLA in Peripheral T Lymphocytes from Patients with Drug–Allergic Reactions 1999 ·International Archives of Allergy and Immunology ·Laura Leyva, Marı́a José Torres, S. Posadas, Irene Luque, Louis Gonzalez, M. Blanca, C. Juárez, Luis F. Santamaria‐Babí	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact